newsfilter
← Latest News
GlobeNewswire·

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

MXCT
  • MaxCyte, Inc. has entered into a definitive agreement to acquire Akron BioProducts LLC from Arcline Investment Management affiliates for total consideration of $151.8 million.
  • The transaction includes $105.0 million in cash, 20,639,733 shares of MaxCyte common stock valued at approximately $26.8 million, and $20.0 million in guaranteed deferred payments payable in January 2028 2029.
  • Akron Bio is a leading supplier of GMP-grade reagents ancillary materials used throughout the cell therapy manufacturing workflow, including products supporting five commercially approved therapies.
  • The acquisition is expected to nearly double MaxCyte's revenue base, expand commercial-stage exposure, increase recurring revenue, and accelerate the path to profitability.
  • Akron Bio is projected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026 with positive cash flow.
  • MaxCyte secured a new credit facility with MidCap Financial of up to $75.0 million, which will fund the combined company's operations through profitability.
  • The combined entity's products are embedded in the workflows of five approved therapies and support over 100 clinical programs with referenced Drug Master Files.
  • The transaction is expected to close before the end of 2026, subject to customary closing conditions.
  • Akron Bio will continue operating under its existing brand with its current leadership team employees playing a key role in the combined company.
  • The deal is not subject to a financing condition or stockholder approval and will be funded using MaxCyte's cash on hand and newly issued stock.
Company
MaxCyte, Inc
Keywords
Nasdaq:MXCT, MaxCyte, Inc